Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells

被引:0
作者
Xu-yuan Li
Ying-cheng Lin
Wan-lan Huang
Chao-qun Hong
Jiong-yu Chen
Yan-jie You
Wei-bing Li
机构
[1] Cancer Hospital of Shantou University Medical College,Department of Internal Medicine
[2] Cancer Hospital of Shantou University Medical College,Department of Laboratory
来源
Medical Oncology | 2012年 / 29卷
关键词
Human nasopharyngeal carcinoma cell line; Invasion; Matrix metalloproteinases; Migration; Vascular endothelial growth factor; Zoledronic acid;
D O I
暂无
中图分类号
学科分类号
摘要
To demonstrate the effect of zoledronic acid in proliferation, invasion, and migration of human nasopharyngeal carcinoma cell HNE-1 and explore the potential role of VEGF, MMP-2, and MMP-9 proteins in vitro. Human nasopharyngeal carcinoma cell HNE-1 was exposed to various concentrations (0–40 μmol/l) of zoledronic acid. Zoledronic acid inhibited proliferation of HNE-1 cells though not in a dose-dependent manner. Zoledronic acid had exerted a dose-dependent effect on the migration and invasion of HNE-1 cells. Both expressions of mRNA and protein of MMP2, MMP9, and VEGF were reduced, respectively, detected by RT-PCR and Western blot assays. These data suggested that zoledronic acid not only inhibited growth but also invasion and migration of HNE-1 cells in vitro. The anti-cancer action of zoledronic acid was partially associated with the suppression of VEGF expression and secretion and downregulating the expression of MMP2 and MMP9.
引用
收藏
页码:714 / 720
页数:6
相关论文
共 61 条
[1]  
Mcderrmott AL(2001)The aetiology of nasopharyngeal carcinoma Clin Otolaryngol Allied Sci 26 82-92
[2]  
Dutt SN(2010)Nasopharyngeal carcinoma: alternative treatment options after disease progression Expert Rev Anticancer Ther 10 377-386
[3]  
Watkinson JC(2010)Treatment approaches to nasopharyngeal carcinoma: a review Anticancer Drugs 21 471-477
[4]  
Arango BA(2010)Nasopharyngeal carcinoma: the next challenges Eur J Cancer 46 1967-1978
[5]  
Castrellon AB(2007)Zoledronic acid—a multiplicity of anti-cancer action Curr Med Chem 14 2126-2135
[6]  
Perez CA(2005)Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity Cancer Res 65 4971-4974
[7]  
Raez LE(2008)Exploring the anti-tumor activity of bisphosphonates in early breast cancer Cancer Treat Rev 34 453-475
[8]  
Santos ES(2009)Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 679-691
[9]  
Caponigro F(2010)Effect of zoledronate on persisting isolated tumor cells in patients with early breast cancer Anticancer Res 30 1807-1813
[10]  
Longo F(2003)New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects Br J Cancer 88 1631-1640